Key Highlights

• Revenue rose 10.7 per cent from A$2,999.4 million, comprising organic growth of 8.4 per cent, 0.4 per cent from acquisitions and divestments, and 1.9 per cent from currency.

• Commodities delivered revenue of A$1,294.2 million, up 18.8 per cent, and underlying segment EBIT of A$381.5 million, up 25.9 per cent, at a Margin of 29.5 per cent.

• Free Cash Flow before net Capital Expenditure was A$674.1 million, up A$83.5 million, with cash conversion of 92 per cent.

• On 18 May 2026 the testing group reported FY26 (year ended 31 March 2026) revenue of A$3,320.1 million and underlying Earnings before interest and tax (EBIT) of A$599.0 million, up 19.3 per cent.

What does ALS (ASX:ALQ) Limited's latest annual result show about Demand for laboratory testing, and how much balance-sheet room has it created? On 18 May 2026 the testing group reported FY26 (year ended 31 March 2026) revenue of A$3,320.1 million and underlying earnings before interest and tax (EBIT) of A$599.0 million, up 19.3 per cent. At the same time, net Debt excluding leases fell to A$1,069.5 million and Leverage dropped to 1.5 times, below its 1.7 to 2.3 times target range. The result points to encouraging momentum in both the Commodities and Life Sciences divisions, alongside a few risks that deserve attention.

The FY26 result

All figures are from ALS's FY26 results released on 18 May 2026 and are in Australian dollars. Revenue rose 10.7 per cent from A$2,999.4 million, comprising organic growth of 8.4 per cent, 0.4 per cent from acquisitions and divestments, and 1.9 per cent from currency. Underlying EBIT was A$599.0 million against A$502.3 million, and the underlying Operating Margin was 18.0 per cent, up 147 basis points on a constant currency basis.

Underlying net profit after tax was A$381.2 million, up 25.8 per cent, and statutory NPAT was A$318.7 million, up 24.4 per cent. The difference reflects A$54.7 million of restructuring and other items, including A$26.6 million of acquisition, integration and divestment costs. Underlying Basic Earnings Per Share were 75.7 cents, and statutory basic EPS 63.3 cents.

The total FY26 Dividend was 42.5 cents, up 10.1 per cent, comprising a 19.4 cent interim paid on 17 December 2025 and a 23.1 cent final payable on 3 July 2026. Both are 30 per cent franked, and the Payout Ratio was 57 per cent of underlying continuing NPAT.

Two engines: Commodities and Life Sciences

ALS earns revenue by testing samples for clients, so volumes follow client activity and regulation rather than a single product price.

Commodities delivered revenue of A$1,294.2 million, up 18.8 per cent, and underlying segment EBIT of A$381.5 million, up 25.9 per cent, at a margin of 29.5 per cent. Within it, Minerals organic revenue grew 20.2 per cent with an EBIT margin of 33.0 per cent, and Industrial Materials organic revenue grew 10.5 per cent. The company links Minerals to base metal demand for the energy transition and demand for premium analytical services, which is the company's own view.

Life Sciences revenue was A$2,025.9 million, up 6.0 per cent, with organic growth of 2.8 per cent. Underlying segment EBIT was A$296.5 million, up 10.2 per cent, at a margin of 14.6 per cent. The mix is uneven. Food organic revenue grew 7.2 per cent and Environmental 2.8 per cent, with PFAS testing at about 6 per cent of revenue and growing in the mid-teens. Pharmaceutical organic revenue fell 1.6 per cent.

The contrast matters. Commodities has the higher margin and faster growth, and is more exposed to the exploration and Mining cycle. Life Sciences is larger by revenue and steadier, but its margin is lower and one sub-segment is shrinking.

Acquisition integration

Recent acquisitions include York, Wessling and Nuvisan. The result states that Wessling integration is tracking ahead of plan, that York's integration challenges are largely remediated, and that the Nuvisan transformation program is complete, with about EUR25 million invested and about EUR25 million of annualised savings. These are management assessments. Integration is a risk that can lift or depress margins, and the improved Life Sciences margin suggests progress, though only 55 basis points.

Cash flow and balance sheet

Free cash flow before net capital expenditure was A$674.1 million, up A$83.5 million, with cash conversion of 92 per cent. Capital expenditure rose 59.4 per cent to A$263 million, of which about A$230 million was for growth. Net debt excluding leases was A$1,069.5 million, down from A$1,424.1 million, and gearing fell to 38.5 per cent from 52.4 per cent. Interest Cover was 13.5 times and Liquidity exceeded A$580 million at 31 March 2026. A net A$367.4 million capital raising was completed in May 2025, and on 8 May 2026 ALS renewed US$50 million (A$72.8 million) of bilateral revolving facilities, leaving pro forma weighted average debt Maturity at 4.0 years.

Net tangible Assets per share were negative A$0.45, excluding right-of-use assets, an improvement from negative A$1.57. The negative figure reflects Goodwill and intangibles from acquisitions.

Sector and competitive position

Testing is a scale Business in which laboratory networks, accreditation and turnaround time are the main competitive tools. The group highlights PFAS regulation and outsourcing trends in Life Sciences.

Outlook

The company gave no quantitative FY27 guidance. Its stated objective is to maximise earnings and Investment returns across all business units.

Risks and what to monitor

The risk section of the report highlights several points. A cyber security incident after year end affected certain IT systems and caused temporary disruption; the group does not currently expect a material financial impact, but the investigation was ongoing. Geopolitical risk trended upward, and ALS holds interests in Russian-based operations. Supply chain risk also increased, with early freight diversions observed. Commercial risk remained elevated but showed signs of moderating, particularly in Environmental, and the cyber risk profile remains high.

Items to monitor:

- The next half-year result, for Minerals volumes and Life Sciences margin.

- Any update on the cyber incident investigation.

- Pharmaceutical trends and Environmental commercial conditions.

- Capital deployment now that leverage is below range.